TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02093039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: decision aid group
Description: The paper-based leaflet DECIDEO is a 12-page pocket leaflet providing scientific information about the advantages and disadvantages of participating in the national breast screening program, understandable by all, constructed to conform with the International Patient Decision Aid Standards
Study: NCT04452448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASIK
Description: All cases were operated upon using Wavelight Allegretto EX-500 excimer laser (Alcon Laboratories, Inc., Fort Worth, TX) with wave front optimized ablation profile WFO. The Moria II microkeratome (Moria, Anthony, France) was used in all cases.
Study: NCT02924324

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wong-Baker FACES® Pain Rating Scale
Description: Nurses will record patient-reported pain scores.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wong-Baker FACES® Pain Rating Scale
Description: Nurses will record patient-reported pain scores.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Post-procedural quality of life (QOL)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-procedural quality of life (QOL)
Study: NCT04985006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: running at moderate intensity
Description: intensity was determined by calculating the subject's heart rate reserve using the formula: ((resting heart rate maximal - resting heart rate) x % of target intensity) + resting heart rate. At moderate intensity, the subject will be asked to run at 50-59% Heart rate reserve (HRR) for 30 minutes from the time the target intensity is reached.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: running at high intensity
Description: intensity was determined by calculating the subject's heart rate reserve using the formula: ((resting heart rate maximal - resting heart rate) x % of target intensity) + resting heart rate. At moderate intensity, the subject will be asked to run at 70-75% HRR for 30 minutes from the time the target intensity is reached.
Study: NCT01802814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR-A + Epratuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR-B + Epratuzumab
Study: NCT03541044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Prototype Mini lozenge
Description: A single dose of a prototype nicotine 2mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Mini Lozenge
Description: A single dose of a 2 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
Study: NCT03315936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: powder for oral solution
Study: NCT01694199

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No Pulsed Radiofrequency Energy (PRFE)
Description: Sham (placebo) with no therapeutic device activity
Study: NCT05527509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Resilience Skills Training (ERST)
Description: The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of RCMP trainers during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Monitoring
Description: Participants in the STC will be assessed for at least 66 months, via full assessments (i.e., self-report surveys, clinical interviews), monthly assessments (i.e., \~20 minute self-report surveys), daily assessments (i.e., \~1 minute self-report surveys), and biometric assessments. The self-monitoring and feedback should be inherently beneficial and should facilitate earlier access to evidence-based care, which is why the STC is considered an active comparator.
Study: NCT01779427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIM
Description: An online, 12 week research study to learn if a computer-based intervention that provides direct attention and metacognitive strategy development can improve attention, memory, and executive control in adolescents with moderate-to-severe TBI who are experiencing attention difficulties post injury.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIM
Description: An online, 12 week research study to learn if a computer-based intervention that provides direct attention and metacognitive strategy development can improve attention, memory, and executive control in adolescents with moderate-to-severe TBI who are experiencing attention difficulties post injury.
Study: NCT00475787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Detuned Ultrasound
Description: US machine is turned on and set at 0 w/cm2
Study: NCT04132388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Reporting
Description: The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.~Subjects will return for evaluation at 12 \& 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit.
Study: NCT02976779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OWC MGC cream
Description: Topical cream containing 3% CBD and 3% THC for Psoriasis treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OWC Control Cream
Description: Topical Cream without active ingredients
Study: NCT04594226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EA combined with medication
Description: Primary acupoints include Ashi points, Jiaji acupoints and Xi-cleft points. Jiaji points on the ipsilateral side will be selected according to the corresponding ganglia involved by HZ. Xi-cleft points will be selected based on the distribution regions of PHN. For pain sites that mainly distributed in the gallbladder meridian, GB36 will be selected. For pain sites that mainly distributed in the stomach meridian, ST34 will be selected. For pain sites that mainly distributed in the gallbladder meridian, BL63 will be selected. For pain sites that mainly distributed in the large intestine meridian, LI7 will be selected. Supplementary acupoints will be chosen based on TCM syndrome differentiation.~Operation: Two paired of acupoints are connected to the EA apparatus. EA parameter is selected as 2/100Hz wave. EA intensity is selected according to the patients' endurance. Needles will be retained and EA will last for 30 mins for each session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication
Description: The dosage of gabapentin starts from 100mg Tid. 100mg-300mg can be increased every 3-7 days and taken in three doses, but the total amount is not more than 1800mg/day. The dosage of gabapentin will be adjusted according to the patient's condition until his pain is effectively controlled. After maintaining the medication for two weeks, the dosage can be gradually reduced and 100mg can be reduced every 3-7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: The dosage of gabapentin starts from 100mg Tid. 100mg-300mg can be increased every 3-7 days and taken in three doses, but the total amount is not more than 1800mg/day. The dosage of gabapentin will be adjusted according to the patient's condition until his pain is effectively controlled. After maintaining the medication for two weeks, the dosage can be gradually reduced and 100mg can be reduced every 3-7 days.
Study: NCT01323010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol - Experimental
Description: The Experimental group will receive higher doses of albuterol in the first hour: 900 mcg (up to 15 kg), 1200 mcg (\> 15 to 20 kg), 1500 mcg (\> 20 to 25 kg) and 1800 mcg (\> 25 kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol - Control
Description: The Control group will receive the following doses of albuterol in the first hour 600 mcg (up to 25 kg) or 1200 mcg (\> 25 kg)
Study: NCT03459898

Intervention type: DEVICE
Group type: OTHER
Intervention: AlignRT system (VisionRT Ltd., London, UK)
Description: To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.

Intervention type: DEVICE
Group type: OTHER
Intervention: AlignRT system (VisionRT Ltd., London, UK)
Description: To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
Study: NCT02240927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Molecular Weight Heparine : Enoxaparine
Description: During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparine and 2.5 mg Warfarin
Description: If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparine and 4mg Warfarin
Description: If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
Study: NCT00836888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: 1mg/kg, 3mg/kg, 10mg/kg and 20mg/kg ONO-4538 infusion cohorts
Study: NCT03641625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscular tissue oxygen saturation guided care
Description: Muscular tissue oxygen saturation monitored at flank and arm will be maintained \> 70% (absolute measurement) and \> baseline throughout the entire procedure.
Study: NCT03404726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2402234
Description: BAY2402234 is a potent and selective small molecule inhibitor of dihydroorotate dehydrogenase. A solution of BAY2402234 will be available to initiate the trial and there are plans to transition to a tablet form of BAY2402234 once it becomes available. Both liquid and tablet formulations of BAY2402234 will be continually administered once daily by mouth in 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2402234
Description: BAY2402234 is a potent and selective small molecule inhibitor of dihydroorotate dehydrogenase. A solution of BAY2402234 will be available to initiate the trial and there are plans to transition to a tablet form of BAY2402234 once it becomes available. Both liquid and tablet formulations of BAY2402234 will be continually administered once daily by mouth in 28 day cycles.
Study: NCT03315936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: powder for oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: Tablet
Study: NCT03404726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2402234
Description: BAY2402234 is a potent and selective small molecule inhibitor of dihydroorotate dehydrogenase. A solution of BAY2402234 will be available to initiate the trial and there are plans to transition to a tablet form of BAY2402234 once it becomes available. Both liquid and tablet formulations of BAY2402234 will be continually administered once daily by mouth in 28 day cycles.
Study: NCT03473639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: In metastatic breast cancer patients, entinostat will be taken orally starting at 3 mg per week and will increase to 5 mg per week in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
Study: NCT03315936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: Tablet
Study: NCT01616875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel + Cisplatin chemotherapy
Description: Cabazitaxel 15mg/m2 followed by cisplatin 70mg/m2 given intravenously on day 1 of each 3 weekly cycle for 4 cycles prior to radical cystectomy.
Study: NCT00829686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Septra
Description: (800/125) PO BID X 7 days
Study: NCT02387996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT02252614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen sodium codein
Description: Pain intensity, contramal consumption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol codein
Description: Pain intensity, contramal consumption

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pain intensity, contramal consumption
Study: NCT00186498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: Patients received a memantine containing capsule starting the day before ECT begins and while receiving ECT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
Study: NCT00977496

Intervention type: PROCEDURE
Intervention: Nasal Swab
Description: Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the anterior vestibule of both nares and processed for S aureus cultures and for bacterial DNA extraction.
Study: NCT01784692

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immulina

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immulina
Study: NCT04132388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subjects will be instructed to take Humira according to the labelled dosing regimen. Treatment will be for 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subjects will be instructed to take Humira according to the labelled dosing regimen. Treatment will be for 26 weeks
Study: NCT01784692

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immulina

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Immulina
Study: NCT00133536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H5N1 Vaccine
Description: Monovalent inactivated subvirion influenza H5N1 vaccine (derived from A/Vietnam/1203/04). Packaged in single-dose vials of 90 mcg/mL (0.7 mL/vial). Dosage 45 mcg/0.5 mL administered intramuscularly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administered intramuscularly.
Study: NCT03912623

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPA Treatment with therapeutic education and physical activity
Description: 3 weeks SPA Treatment plus therapeutic education plus physical activity

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Week end
Description: access to the station for a week end after maintenance of usual treatment during 6 months
Study: NCT03473639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: In metastatic breast cancer patients, capecitabine will be taken by mouth starting at 800 mg/m2 twice a day for 14 days per cycle and increase to 1000 mg/m2 (for 14 days per cycle) in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
Study: NCT02741674

Intervention type: PROCEDURE
Intervention: Roux-en-y gastric bypass (RYGB) - historical
Description: Participant has had RYGB, as identified using existing data
Study: NCT04035200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V117957 tablets
Description: V117957 tablets taken orally at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V117957 tablets
Description: V117957 tablets taken orally at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets to match V117957
Study: NCT03383562

Intervention type: PROCEDURE
Intervention: operation in different stages of the day
Description: operation was arranged in the morning ,afternoon or at night

Intervention type: PROCEDURE
Intervention: operation in different stages of the day
Description: operation was arranged in the morning ,afternoon or at night

Intervention type: PROCEDURE
Intervention: operation in different stages of the day
Description: operation was arranged in the morning ,afternoon or at night
Study: NCT00975052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin phosphate
Description: 100 mg sitagliptin daily for two days in one out of four treatment periods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin
Description: 500 mg twice daily on Day 1 and 1000 mg once daily on Day 2 in one of four treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sitagliptin and metformin
Description: 100 mg sitagliptin once daily and 500 mg metformin twice daily on Day 1 and 100 mg sitagliptin once daily and 1000 mg metformin once daily on Day 2 in one of four treatment periods.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Placebo only on Days 1 and 2 in one of four treatment periods.
Study: NCT01105013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole
Description: Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
Study: NCT00303563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P38 Inhibitor (4)
Description: 50mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P38 Inhibitor (4)
Description: 150mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P38 Inhibitor (4)
Description: 300mg po qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po qd
Study: NCT01711957

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Standardized technique of liver transplantation Organ procurement follow the rules of the Swiss transplant society
Study: NCT03187015

Intervention type: DRUG
Group type: OTHER
Intervention: Entinostat
Description: HDAC (histone deacetylase inhibitor)

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: benzodiazepine central nervous system (CNS) depressant
Study: NCT04599738

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wheat muffin
Description: Participants consumed a control muffin made of wheat flour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finger millet grain muffin
Description: Participants consumed a test muffin made of finger millet grain and wheat flour.
Study: NCT03788460

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02741674

Intervention type: PROCEDURE
Intervention: Adjustable gastric banding (AGB) - historical
Description: Participant has had AGB, as identified using existing data
Study: NCT00825032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive PR
Description: Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UEET
Description: Experimental program consisting of 15 additional daily sessions of unsupported UEET.